About sphingotec GmbH
sphingotec GmbH (Hennigsdorf, Germany) develops innovative biomarkers for prediction, diagnosis and therapy monitoring of AKI, congestive heart failure and septic shock. The company, founded by Dr. Andreas Bergmann in 2002, has also in its portfolio biomarkers which can predicts risks of obesity, breast cancer and cardiovascular diseases.
Founder and CEO: Andreas Bergmann
2 articles with sphingotec GmbH
- Diagnostics company sphingotec GmbH successfully closed €20 million growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners
sphingotec Announces Collaboration With Mayo Clinic for Evaluation and Use of Biomarkers to Improve Diagnosis of Certain Diseases, Including Kidney Disease, Breast Cancer, Sepsis, and Cardiovascular Disease
Through this agreement, Mayo Clinic will evaluate the biomarkers penKid and three others for research and potential routine clinical use.